Antineoplastic Agents, Immunological
"Antineoplastic Agents, Immunological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000074322
|
| MeSH Number(s) |
D27.505.954.248.384
|
| Concept/Terms |
Antineoplastics, Monoclonal Antibodies- Antineoplastics, Monoclonal Antibodies
- Antibodies Antineoplastics, Monoclonal
- Monoclonal Antibodies Antineoplastics
- Monoclonal Antibodies, Antineoplastic
- Antineoplastic Monoclonal Antibodies
- Antineoplastic MAbs
- Antineoplastics, Monoclonal Antibody
- Monoclonal Antibody Antineoplastics
- MAbs, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Immunological".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Immunological".
This graph shows the total number of publications written about "Antineoplastic Agents, Immunological" by people in this website by year, and whether "Antineoplastic Agents, Immunological" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 2 | 2 |
| 2017 | 49 | 16 | 65 |
| 2018 | 86 | 22 | 108 |
| 2019 | 46 | 24 | 70 |
| 2020 | 7 | 6 | 13 |
| 2021 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents, Immunological" by people in Profiles.
-
The impact of the Covid-19 pandemic on quality of life in skin cancer patients. PLoS One. 2021; 16(8):e0255501.
-
Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix. Eur J Cancer. 2021 10; 156:119-121.
-
COVID-19 Patient Acceptance to Monoclonal Antibody Infusion: A Single Medical Center Experience. South Med J. 2021 08; 114(8):464.
-
Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):e810-e816.
-
Restoring NK cells functionality via cytokine activation enhances cetuximab-mediated NK-cell ADCC: A promising therapeutic tool for HCC patients. Mol Immunol. 2021 09; 137:221-227.
-
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics. J Clin Pharmacol. 2021 08; 61(8):1096-1105.
-
Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. Front Immunol. 2021; 12:711915.
-
Vaccinated but Not Protected-Living Immunocompromised During the Pandemic. JAMA. 2021 Jun 22; 325(24):2443-2444.
-
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. Leukemia. 2021 09; 35(9):2710-2714.
-
SARS-CoV-2 Monoclonal Antibodies in Children: Ethical Considerations. Clin Ther. 2021 06; 43(6):e157-e162.